89zr-dfo-9e7.4

89Zr-DFO-9E7.4 is a radiolabeled monoclonal antibody-based imaging agent used for immuno-PET (positron emission tomography) imaging. It consists of the anti-CD138 monoclonal antibody 9E7.4 conjugated to the chelator desferrioxamine (DFO), which is then labeled with the positron-emitting radionuclide zirconium-89. The agent binds specifically to the CD138 antigen, prevalent on multiple myeloma cells, enabling targeted in vivo imaging of myeloma lesions through PET. The agent demonstrates both high tumor uptake and background tissue distribution in preclinical models. It is primarily researched as a tool for non-invasive detection, disease assessment, and treatment monitoring in multiple myeloma. The developer of the original antibody (9E7.4) and radiochemistry is academic, with no commercial manufacturer identified in available sources[1][2][6].

Other names

zirconium-89 desferrioxamine-9E7.4zirconium89 desferrioxamine-9E7.4zirconium 89 desferrioxamine-9E7.4zirconium-89 DFO-9E7.4zirconium89 DFO-9E7.4zirconium 89 DFO-9E7.4